Contrast-enhanced breast MRI (CE-MRI) may soon change the management of high-risk breast lesions. Specifically, recent data strongly supports the use of Breast MRI B3 lesions to rule out malignancy in women diagnosed with B3 lesions at image-guided biopsy. Formerly, patients with these uncertain findings often required surgical excision to confirm a definitive diagnosis. Consequently, this systematic review and meta-analysis demonstrate how a negative CE-MRI can safely identify a substantial proportion of patients who can avoid unnecessary surgery. This shift justifies a move toward active surveillance protocols.
Understanding the Risk of B3 Lesions
High-risk B3 lesions are a heterogeneous group of findings that carry an uncertain malignant potential. These lesions are typically detected through screening and then diagnosed via core needle biopsy. Because the malignant upgrade rate can range between 10% and 35%, initial management often required surgical excision to definitively rule out cancer. However, the risk of malignancy varies greatly across individual B3 subtypes. For example, some lesions without atypia, like radial scars, show a low upgrade rate of about 6%. Conversely, lesions with atypia, such as atypical ductal hyperplasia (ADH), can have an upgrade rate as high as 32%. Therefore, clinicians are actively searching for non-invasive methods to better stratify this risk and avoid surgery for low-risk B3 findings. The diagnostic accuracy of CE-MRI offers a potential solution.
High Sensitivity of Breast MRI B3 Lesions
CE-MRI demonstrates remarkably high sensitivity and a very low Negative Likelihood Ratio (NLR) for detecting malignancy within B3 lesions. A meta-analysis of over 2,000 lesions reported a pooled sensitivity of 0.98, which indicates a high degree of accuracy. Furthermore, the pooled NLR was extremely low at 0.04. This finding is clinically important because the NLR helps estimate the likelihood of disease after a negative test result. Consequently, a negative CE-MRI can exclude malignancy up to a pretest probability of nearly 50%. Clinicians previously used a 2% malignancy threshold to downgrade a BI-RADS 4 finding to BI-RADS 3 (requiring only surveillance). The high sensitivity and low NLR of CE-MRI ensure that a negative MRI result aligns with this 2% threshold, confirming the safety of a non-surgical approach.
Guiding Management Toward Active Surveillance
The high Negative Predictive Value (NPV) of CE-MRI, reported in some studies as high as 96–98%, provides the confidence needed for a management shift. Therefore, a negative MRI is a precise indicator of benignity for B3 lesions and supports active surveillance over surgical excision. This non-invasive approach reduces patient morbidity, decreases patient anxiety, and saves costs for the healthcare system. Consequently, the multidisciplinary team must correlate the radiological findings with the pathological results. Ultimately, a negative CE-MRI helps identify the substantial group of patients with B3 lesions who may safely proceed to active surveillance.
Frequently Asked Questions
Q1: What are B3 breast lesions?
B3 lesions are a heterogeneous group of abnormal findings diagnosed on breast biopsy. They are classified as lesions of uncertain malignant potential because they have a variable risk of progressing to or co-existing with breast cancer, ranging from approximately 10% to 35%.
Q2: Why is breast MRI useful for B3 lesions?
Contrast-enhanced MRI (CE-MRI) has a very high sensitivity (0.98) and a low Negative Likelihood Ratio (NLR) for malignancy. This means a negative MRI result can safely rule out cancer, allowing a patient to move from recommended surgery to active surveillance.
Q3: Which B3 lesions can avoid surgery with a negative MRI?
A negative CE-MRI can safely rule out malignancy up to a pretest probability of 48–55%. This includes patients with various B3 subtypes, helping the multidisciplinary team confirm that the risk of upgrade is below the 2% threshold for intervention.
References
- Vatteroni G et al. Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery: a systematic review and meta-analysis. Eur Radiol. 2026 Jan 17. doi: 10.1007/s00330-025-12291-9. PMID: 41545805.
- Kuhl C. et al. High-Risk Breast Lesions at Imaging-Guided Needle Biopsy: Usefulness of MRI for Treatment Decision. AJR Online. 2007.
- Fazzari M. et al. High Risk (B3) Breast Lesions: What Is the Incidence of Malignancy for Individual Lesion Subtypes? A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2018.
- Sanguineti R. et al. The role of MRI in the management of patients with a histological diagnosis of B3 breast lesion after vacuum-assisted biopsy: A case report and a brief review of the literature. Breast J. 2025.